INTERVENTIONAL VASCULAR CORPORATE AND REGIONAL PRESS RELEASES

Please find below a list of our press releases.

26 Jan 2017

New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure ...

BTG International Canada Inc., part of global specialist healthcare company BTG (LSE: BTG), today announced the Canadian commercial launch of Varithena™ (polidocanol injectable foam), a drug/device combination product used to treat varicose veins.

26 Jan 2017

Nouveau traitement des varices offrant une intervention non chirurgicale à ef...

BTG International Canada Inc., qui fait partie de BTG, une entreprise internationale de soins de santé spécialisés (LSE : BTG), a annoncé aujourd’hui le lancement sur le marché canadien de Varithena™ (mousse injectable à base de polidocanol), une combinaison de médicament et d’appareil utilisé pour traiter les varices.

9 Jan 2017

First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS®...

BTG plc (LSE: BTG), the global specialist healthcare company, today announced the first patients diagnosed with Pulmonary Embolism (PE) to be treated in Hong Kong using the newly available EKOS® system.

24 Aug 2015

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovasc...

EKOS Corporation, a BTG International group company (BTG plc; LSE: BTG), announced the publication of results of the SEATTLE II trial in the JACC: Cardiovascular Interventions. The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism (PE) improves right heart function, reduces blood clot size, and decreases pulmonary hypertension, in patients with intermediate to high risk PE. Importantly, no patient experienced intracranial hemorrhage, a serious adverse experience related to full-dose thrombolysis treatment.

24 Aug 2015

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovasc...

EKOS Corporation, a BTG International group company (BTG plc; LSE: BTG), announced the publication of results of the SEATTLE II trial in the JACC: Cardiovascular Interventions. The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism (PE) improves right heart function, reduces blood clot size, and decreases pulmonary hypertension, in patients with intermediate to high risk PE. Importantly, no patient experienced intracranial hemorrhage, a serious adverse experience related to full-dose thrombolysis treatment.

6 Aug 2015

11 Aug 2014

First Varicose Vein Patient Treated with FDA-Approved Varithena®

BTG International Inc. announces that the first varicose vein patient has been treated with Varithena®

11 Jun 2014

EKOS Initiates a Pivotal New Study in Patients with Chronic Deep Vein Thrombo...

EKOS Corporation, a BTG International group company (BTG plc; LSE: BTG), announces the start of patient enrollment for the ACCelerated ThrombolySiS for Post-Thrombotic Syndrome using the EKOS® System (ACCESS PTS) Study.

23 May 2014

EkoSonic® Endovascular System receives FDA Clearance for the T...

EKOS Corporation, a BTG International group company announced that the U.S. Food and Drug Administration (FDA) has cleared the EkoSonic® Endovascular System for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids.

30 Mar 2014

Acute Pulmonary Embolism Trial Confirms Safety and Efficacy of Ultrasound Acc...

EKOS Corporation, a BTG International group company (BTG plc (LSE: BTG)), notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.